Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma – Hastings Tribune

Spread the love

Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma Hastings Tribune

ALAMEDA, Calif. & PARIS–(BUSINESS WIRE)–Dec 5, 2018–Exelixis, Inc. (Nasdaq:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced the initiation …

…read more

Source:: Alameda, California News By Google News

Start a Conversation

[ghozylab-instagram feed=26796]